SCH: INT Wireless Implantable Electronic Biosensors for Tumor Monitoring
SCH: INT Wireless Implantable Electronic Biosensors for Tumor Monitoring
批准号:
8897547
负责人:
David Blaauw
金额:
$46.09万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-22 至 2018-08-31
关键词:
Acid-Base EquilibriumAreaBiochemicalBiological MarkersBiopsyBiosensorCancer BiologyCharacteristicsChargeChemotherapy-Oncologic ProcedureClinicalDevelopmentDevicesDisciplineDiseaseEducationEducational CurriculumElectronicsEnvironmentGenerationsHarvestHealthcareImageImplantIndividualInfrared RaysInstructionIntercellular FluidLifeLiquid substanceMalignant NeoplasmsMeasuresMedicalMedical ResearchMedicineMetabolicMethodsMonitorOrganPatientsPhysiologyPositioning AttributePositron-Emission TomographyPower SourcesResearch PersonnelSolid NeoplasmSystemTechnologyTimeTissuesTreatment FailureWireless Technologyage groupcancer therapychemotherapydesignextracellularimplantable deviceimprovedin vivointerstitialmalignant breast neoplasmmeetingsmouse modelpreclinical studypressureprogramsresponsesealsensorsuccesstransmission processtreatment responsetumortumor metabolismvoltage
中文摘要
英文摘要
DESCRIPTION (provided by applicant): Technologies to non-invasively, continuously measure biochemical, metabolic, and biophysical changes in living tissues and organs have the capability to transform medical research and health care. Imaging and biopsies currently are the predominant methods to analyze disease status. Since these approaches provide only a limited number of snapshots over extended periods of time, researchers and clinicians may miss critical changes in physiology and disease status. We propose to overcome this fundamental medical problem by developing a new generation of ultra-low power, wireless, implantable, mm- scale biosensors for real-time, continuous monitoring of interstitial fluid pressure or extracellular pH n tumors. Elevated interstitial fluid pressure and acidic pH are characteristic features of almost al solid tumors, and prior studies suggest that changes in these parameters may be sensitive, early biomarkers for treatment response in many different malignancies. We will design sensors for percutaneous insertion into a tumor before starting chemotherapy. Sensors will remain in place over the multi-week course of treatment, continuously recording pressure or extracellular pH for periodic wireless transmission to an external readout device. We expect changes in interstitial pressure or pH in tumors will occur before alterations in tumor size and at least as soon as changes in tumor metabolism measured by clinical positron emission tomography (PET) imaging. To meet the challenge of extended tumor monitoring, we will advance our biosensor technology in four new areas: 1) through-tissue energy harvesting of infrared (IR) radiation, which will enable implantable devices to operate essentially perpetually in a non-invasive manner; 2) a new self-starting voltage converter to allow system charging after encapsulation is completed, facilitating high quality sealing of the electronics from the in vivo environment; 3) new pressure sensing and pH readout circuits for stable readout under unregulated sensor power supplies; and 4) pre-clinical studies to determine response to therapy in a mouse model of breast cancer. The combined expertise of our multi-disciplinary team uniquely positions us to develop transformative new biosensor technology for continuous monitoring of tumor environments, which will advance understanding of cancer biology and ultimately improve personalized cancer therapy. RELEVANCE (See instructions): We will develop mm-scale electronic biosensors that can be implanted into a tumor to continuously monitor response to several weeks of cancer therapy. By measuring changes in fluid pressure or acid-base balance in a tumor, we expect to detect success or failure of treatment within days of beginning chemotherapy. We expect this biosensor technology ultimately will provide a cheaper, more accurate method to determine efficacy of cancer therapy, allowing doctors to tailor chemotherapy protocols to individual patients and increase patients cured of cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optical neural motes to enable high density recording through intact dura in a nonhuman primate
-
批准号:10516965
-
项目类别:
-
资助金额:$257.28万
-
财政年份:2022
-
负责人:David Blaauw
-
依托单位:
A 100μm Scale Single Unit Neural Recording Probe Using IR-Based Powering and Communication
-
批准号:9763599
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2018
-
负责人:David Blaauw
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: